ENSACOVE (Ensartinib Hydrochloride) Patent Expiration, LOE Window & CMS Spending

ENSACOVE (Ensartinib Hydrochloride) by Xcovery Holdings: FDA Orange Book core substance LOE 2037-06-01, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $18,631 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorXcovery Holdings
FDA Application & PathwayN218171 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2037-06-01
Last Listed Patent or Exclusivity Date2037-06-01
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($18,631 intro WAC)